**Study Purpose:** This research aims to test the safety and effects of two medicines, **tislelizumab** and **SX-682**, for people with a specific type of pancreas cancer that can be surgically removed. **Tislelizumab** is a medicine that helps the immune system attack cancer cells, while **SX-682** blocks proteins on cells that might help cancer spread. **Who Can Join:** Adults 18 and older with newly diagnosed pancreas cancer that can be surgically removed may join. Participants should be in good health overall, agree to a tumor biopsy (a small tissue sample), and use birth control if needed. Those who have already had certain treatments or health issues like serious infections, other cancers, or autoimmune diseases can't join. **Key Points:** - **Duration and Visits:** Participants will need to attend regular study visits for monitoring and tests. - **Compensation:** Information on payment for participation isn't provided here. - **Risks:** Possible side effects from the study drugs include immune reactions or other health risks, as with any clinical trial, but it's monitored closely by doctors. If you're interested, consider discussing with your doctor to see if this study might be a good fit for you.